TAM Receptor | 陶素生化

TAM Receptor

T12650	R916562	R916562 is an orally active and selective Axl/VEGF-R2 inhibitor with IC50s of 136 nM and 24 nM, respectively. R916562 has anti-angiogenesis and anti-metastasis.
T12925	Sitravatinib malate	Sitravatinib malate is an orally bioavailable receptor inhibitor of tyrosine kinase (RTK) (IC50s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Ax
T15822	Ly93	Ly93 is a selective and orally active inhibitor of sphingomyelin synthase 2 (SMS2) (IC50: 91 nM).
T16806	RU-302	RU-302 is a pan inhibitor of TAM. RU-302 potently blocks Gas6-inducible Axl receptor activation with a low micromolar IC50 in cell assays and suppresses lung cancer tumor growth.
T17205	UNC2541	UNC2541 is a potent and Mer tyrosine kinase (MerTK)-specific inhibitor. It also binds in the MerTK ATP pocket (IC50: 4.4 nM). UNC2541 inhibits phosphorylated MerTK (pMerTK; EC50, 5
T1797	Cabozantinib Malate	Cabozantinib S-malate is the s-malate salt form of cabozantinib, an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activ
T2005	TP0903	TP-0903 is a potent and selective Axl kinase inhibitor.
T2311	LDC1267	LDC1267 is a excellently specific TAM(Tyro3, Axl and Mer) kinase inhibitor, for Mer( IC50<5 nM), Tyro3(IC50=8 nM), and Axl(IC50=29 nM).
T2586	Cabozantinib	Cabozantinib (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt3 (IC50s: 0.035, 1.3, 4.6, 7 and 11.3 nM).
T2620	G749	G-749, a new-type FLT3 inhibitor, exhibits effective and sustained inhibition of the FLT3 wild type and mutants.
T2629	UNC2881	UNC2881 is a specific Mer tyrosine kinase inhibitor (IC50: 4.3 nM). It is about 83- and 58-fold higher selectivity than Axl and Tyro3, respectively.
T2699	BMS777607	BMS-777607 is a Met-related inhibitor for c-Met/Axl/Ron/Tyro3 (IC50: 3.9/1.1/1.8/4.3 nM). BMS-777607 has been investigated for the basic science of Malignant Solid Tumour.
T3274	S49076	S49076 is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3, blocking cellular phosphorylation of MET, AXL, and FGFRs.
T3512	S49076 HCl	S49076 is an effective inhibitor of MET, AXL/MER, and FGFR1/2/3. S49076 potently blocked cellular phosphorylation of MET, AXL, and FGFRs and inhibited downstream signaling in vitro
T4213	NCT503	NCT-503 is an inhibitor of 3-phosphoglycerate dehydrogenase (PHGDH), inhibiting serine synthesis from 3-phosphoglycerate in cells.
T4349	Sitravatinib	Sitravatinib (MGCD516) is an inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Met, c-Kit, PDGFRα/β, PDGFR, and Axl.
T4409	Gilteritinib	Gilteritinib is a potent inhibitor at the FMS-related tyrosine kinase 3 (FLT3) and AXL tyrosine kinase receptors (IC50 = 0.29 nM and <1 nM, respectively). In preClinicalal studies,
T4419	UNC2025 2HCl (1429881-91-3(free base))	UNC2025 is a potent and orally bioavailable Mer/Flt3 dual inhibitor with IC50 of 0.8/0.74 nM for Mer/Flt3.
T4426	CEP40783	CEP-40783 is an effective, specific and orally active AXL/c-Met inhibitor (IC50: 7/12 nM). It also inhibits MER and TYRO3 (IC50: 29/19 nM).
T5164	Cabozantinib hydrochloride (849217-68-1(free base))	Cabozantinib (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt4 (IC50s: 0.035, 1.3, 4.6, 7 and 6 nM).
T6120	Pralatrexate	Pralatrexate is a folate analogue inhibitor of dihydrofolate reductase (DHFR) exhibiting high affinity for reduced folate carrier-1 (RFC-1) with antineoplastic and immunosuppressiv
T6121	Tepotinib	Tepotinib is an inhibitor of MET tyrosine kinase with potential antineoplastic activity.
T6269	Bemcentinib	R428 is a selective inhibitor of Axl (IC50: 14 nM) and has been investigated for the treatment of NSCLC.
T6907	NPS1034	NPS-1034 is a dual Met/Axl inhibitor with IC50 of 48 nM and 10.3 nM, respectively.
T6982	SGI7079	SGI-7079 is a new selective Axl inhibitor. SGI-7079 can be a dose-dependent manner inhibited growth of tumors. It is also a potential therapeutic target for EGFR inhibitor resistan
T7007	UNC2025	UNC-2025（ IC50 of 0.74 nM and 0.8 nM） is a potent and orally bioavailable dual MER/FLT3 inhibitor. UNC-2025 is about 20-fold selectivity higher than Axl and Tyro3.
T7379	2-D08	2-D08 is a synthetic flavone that inhibits sumoylation, also inhibits Axl with an IC50 of 0.49 nM.2-D08 showed anti-aggregatory and neuroprotective effect.
T7425	RU-301	RU-301 is a novel pan-tam inhibitor
T8327	ONO-7475	ONO-7475 is an inhibitor with high specificity for anexelekto and MER tyrosine kinase
TQ0021	Ningetinib	Ningetinib (CT053PTSA) is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.
TQ0041	Ningetinib Tosylate	Ningetinib Tosylate is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.